Featured Research

from universities, journals, and other organizations

High adherence to HIV prophylaxis may raise efficacy for couples where one partner has HIV

Date:
September 10, 2013
Source:
Public Library of Science
Summary:
High adherence to antiretroviral pre-exposure prophylaxis is associated with a high level of protection from HIV acquisition by HIV-uninfected partners in heterosexual couples where only one of the partners is HIV positive, according to a new study.

High adherence to antiretroviral pre-exposure prophylaxis (PrEP) is associated with a high level of protection from HIV acquisition by HIV-uninfected partners in heterosexual couples where only one of the partners is HIV positive, according to a study published in this week's PLOS Medicine.

The study, which was led by Jessica Haberer, from Harvard Medical School, Boston, United States, included 1,147 HIV-uninfected participants who were enrolled in three Ugandan sites of the Partners PrEP Study- a randomized controlled trial to determine efficacy and safety of PrEP. All participants had a partner who was HIV-positive. These participants were a convenience sample reflecting 66% of all participants in the study sites (they were not randomized as part of this substudy). They were actively monitored for adherence to antiretroviral drugs and received adherence counselling throughout the study, which was intensified if unannounced pill count adherence fell below 80%.

Several randomized controlled trials in various populations (i.e. men who have sex with men, women at high risk for HIV) have shown that PrEP has provided varying levels of protection against HIV infection. One possible explanation for this varying efficacy is differential adherence to the antiretroviral drugs. Within this substudy, where adherence to antiretroviral drugs was very high (99% by unannounced pill counts and 97% by electronic monitoring), only 14 individuals became HIV-positive during an average follow up of 11 months per participant, and all of these individuals were taking a placebo drug.

Although the study has some limitations, such as the non-randomized nature of the study and limitations inherent in any form of adherence monitoring, the findings indicate that the high level of PrEP adherence achieved in the setting of active adherence monitoring and counselling support was associated with a high level of protection from HIV acquisition by the HIV-uninfected partner in heterosexual serodiscordant couples.

The authors note, "These data provide further support that PrEP is highly efficacious at preventing HIV acquisition when it is taken."

The authors conclude, "Proper support and assessment of adherence will be critical for determining efficacy of PrEP outside of clinical trials. This data will be important for guiding ethical decisions about resource allocation for both prevention and treatment of HIV."


Story Source:

The above story is based on materials provided by Public Library of Science. Note: Materials may be edited for content and length.


Journal Reference:

  1. Jessica E. Haberer, Jared M. Baeten, James Campbell, Jonathan Wangisi, Elly Katabira, Allan Ronald, Elioda Tumwesigye, Christina Psaros, Steven A. Safren, Norma C. Ware, Katherine K. Thomas, Deborah Donnell, Meighan Krows, Lara Kidoguchi, Connie Celum, David R. Bangsberg. Adherence to Antiretroviral Prophylaxis for HIV Prevention: A Substudy Cohort within a Clinical Trial of Serodiscordant Couples in East Africa. PLoS Medicine, 2013; 10 (9): e1001511 DOI: 10.1371/journal.pmed.1001511

Cite This Page:

Public Library of Science. "High adherence to HIV prophylaxis may raise efficacy for couples where one partner has HIV." ScienceDaily. ScienceDaily, 10 September 2013. <www.sciencedaily.com/releases/2013/09/130910205426.htm>.
Public Library of Science. (2013, September 10). High adherence to HIV prophylaxis may raise efficacy for couples where one partner has HIV. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2013/09/130910205426.htm
Public Library of Science. "High adherence to HIV prophylaxis may raise efficacy for couples where one partner has HIV." ScienceDaily. www.sciencedaily.com/releases/2013/09/130910205426.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins